Drug Price Trends for FLUVOXAMINE ER

Average Pharmacy Cost for FLUVOXAMINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FLUVOXAMINE ER 100 MG CAPSULE	27241-0274-30	5.56508	EACH	2025-03-19
FLUVOXAMINE ER 100 MG CAPSULE	10370-0175-11	5.56508	EACH	2025-03-19
FLUVOXAMINE ER 150 MG CAPSULE	69452-0183-13	5.50769	EACH	2025-03-19

Market Analysis and Price Projections for Fluvoxamine ER

Introduction to Fluvoxamine ER

Fluvoxamine, marketed in its extended-release (ER) form as fluvoxamine ER, is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat obsessive-compulsive disorder (OCD), depression, and other anxiety disorders. This medication works by increasing the levels of serotonin in the brain, which helps in reducing the symptoms of these conditions[1][3].

Market Growth and Forecast

The fluvoxamine market, including its ER formulation, is expected to experience significant growth over the forecast period. Here are some key points:

• Forecast Period: The market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 4% from 2022 to 2029[1].
• Global Market Size: The fluvoxamine market is projected to expand from $0.74 billion in 2023 to $1.2 billion by 2032[4].
• Drivers: The rise in prevalence of anxiety and depression, increasing geriatric population, and growing healthcare expenditure are major drivers for this market growth. Additionally, the increasing incidence of social anxiety disorder and rising awareness about mental health will positively impact the market[1].

Segmentation and Market Insights

The fluvoxamine market is segmented based on several factors:

• Drug Class: Fluvoxamine falls under the SSRI category, which is a significant segment within the antidepressant market[1].
• Application: The primary applications include OCD, depression, post-traumatic stress disorder (PTSD), and other anxiety disorders[1][3].
• Demographic: The market is segmented into adult, pediatric, and geriatric populations. The geriatric segment is expected to grow due to the increasing age of the population and higher prevalence of mental health disorders in this age group[1][4].
• Dosage Form: Fluvoxamine ER is available in tablet and capsule forms, with extended-release capsules being a preferred option for its convenience and efficacy[1][3].
• Distribution Channel: The market is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies are expected to grow due to increasing consumer preference for convenience and cost savings[1][4].

Regional Analysis

• North America: This region dominates the fluvoxamine market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure[1].
• Asia-Pacific: This region is expected to grow significantly due to increasing research and development activities and the rising prevalence of OCD and other mental health disorders[1].

Price Projections and Cost Analysis

The cost of fluvoxamine ER can vary based on the dosage form, strength, and distribution channel:

• Extended-Release Capsules:
  • 100 mg: Prices range from $189.22 for 30 capsules, with a per-unit cost of $6.31[2].
  • 150 mg: Prices range from $198.28 for 30 capsules, with a per-unit cost of $6.61[2].
• Oral Tablets:
  • 25 mg: Prices start from $78.59 for 100 tablets, with a per-unit cost of $0.79[2].
  • 50 mg: Prices start from $91.85 for 100 tablets, with a per-unit cost of $0.92[2].
  • 100 mg: Prices start from $28.96 for 30 tablets, with a per-unit cost of $0.97[2].

Challenges and Opportunities

• Challenges: High drug costs and side effects such as diarrhea, headache, indigestion, nausea, and others are significant challenges. Lack of awareness about mental health treatments also hampers market growth[1].
• Opportunities: The rise in research and development activities and ongoing clinical trials provide beneficial opportunities for the fluvoxamine market. Recent studies, such as the TOGETHER trial, have also indicated a potential therapeutic role of fluvoxamine in treating COVID-19, which could expand its market scope[1][5].

Clinical and Therapeutic Use

• Indications: Fluvoxamine ER is indicated for the treatment of OCD, with efficacy demonstrated in several clinical studies. It is also used for treating depression and other anxiety disorders[3].
• Dosage and Administration: The recommended starting dose for adults is 100 mg at bedtime, with weekly increases of 50 mg as tolerated, not to exceed 300 mg/day. For pediatric patients and those with hepatic impairment, dose adjustments are necessary[3].

Patient Epidemiology and Market Impact

The increasing prevalence of mental health disorders is a key factor driving the demand for fluvoxamine ER. For instance, the rise in OCD cases and the growing awareness about the importance of mental health treatment are expected to increase the market size. Additionally, the demographic shift towards an aging population will further contribute to the market growth[1][4].

Key Takeaways

• The fluvoxamine market is expected to grow significantly due to increasing prevalence of mental health disorders and rising healthcare expenditure.
• North America and Asia-Pacific are key regions driving market growth.
• High drug costs and side effects are significant challenges, but ongoing research and clinical trials offer opportunities for market expansion.
• Fluvoxamine ER is primarily used for treating OCD, depression, and other anxiety disorders.

Frequently Asked Questions (FAQs)

1. What is fluvoxamine ER used for? Fluvoxamine ER is used primarily for the treatment of obsessive-compulsive disorder (OCD), depression, and other anxiety disorders.

2. What are the common side effects of fluvoxamine ER? Common side effects include diarrhea, headache, indigestion, nausea, dry mouth, stomach-ache, weight loss, dizziness, and fatigue.

3. How is fluvoxamine ER administered? The recommended starting dose for adults is 100 mg at bedtime, with weekly increases of 50 mg as tolerated, not to exceed 300 mg/day.

4. What are the key drivers for the fluvoxamine market growth? Key drivers include the rise in prevalence of anxiety and depression, increasing geriatric population, and growing healthcare expenditure.

5. Which regions are expected to dominate the fluvoxamine market? North America currently dominates the market, while the Asia-Pacific region is expected to grow significantly in the forecast period.

Cited Sources

1. Data Bridge Market Research - Global Fluvoxamine Market - Industry Trends and Forecast to 2029
2. Drugs.com - Fluvoxamine Prices, Coupons, Copay Cards & Patient Assistance
3. Drugs.com - Fluvoxamine ER Capsules: Package Insert / Prescribing Info
4. Market Research Future - Fluvoxamine Market Size, Share Forecast 2032
5. The Lancet - Effect of early treatment with fluvoxamine on risk of emergency care ...